Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) insider Andrew Hollman Meyer sold 3,334 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total transaction of $107,188.10. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,640,768.85. The trade was a 3.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Andrew Hollman Meyer also recently made the following trade(s):
- On Monday, February 3rd, Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86.
- On Thursday, January 2nd, Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92.
Janux Therapeutics Price Performance
JANX stock opened at $31.50 on Thursday. Janux Therapeutics, Inc. has a 1 year low of $29.63 and a 1 year high of $71.71. The company has a market cap of $1.65 billion, a P/E ratio of -26.92 and a beta of 3.16. The firm has a 50-day moving average of $42.23 and a 200 day moving average of $47.67.
Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Janux Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of JANX. Mirae Asset Global Investments Co. Ltd. grew its holdings in Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock worth $87,000 after purchasing an additional 339 shares during the period. Nisa Investment Advisors LLC grew its holdings in shares of Janux Therapeutics by 639.5% during the third quarter. Nisa Investment Advisors LLC now owns 20,343 shares of the company's stock valued at $924,000 after buying an additional 17,592 shares during the last quarter. Chicago Partners Investment Group LLC purchased a new stake in shares of Janux Therapeutics during the third quarter valued at approximately $239,000. Victory Capital Management Inc. grew its holdings in shares of Janux Therapeutics by 143.4% during the third quarter. Victory Capital Management Inc. now owns 29,745 shares of the company's stock valued at $1,351,000 after buying an additional 17,525 shares during the last quarter. Finally, Plato Investment Management Ltd grew its holdings in shares of Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company's stock valued at $54,000 after buying an additional 187 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company's stock.
Analysts Set New Price Targets
A number of research analysts have recently commented on the stock. Scotiabank reduced their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. Leerink Partnrs upgraded shares of Janux Therapeutics to a "strong-buy" rating in a research report on Friday, November 22nd. William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Leerink Partners upped their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 3rd. Finally, Lifesci Capital upgraded shares of Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $88.00.
Check Out Our Latest Stock Report on Janux Therapeutics
About Janux Therapeutics
(
Get Free Report)
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
